Melloidosis

Disclaimer: This information is intended for educational and reference purposes for healthcare professionals. It is not a substitute for clinical judgment, patient-specific assessment, or consultation with relevant specialists. Always adhere to local guidelines and monitor individual patient responses.

---

Overview

Definition

Melioidosis (or Whitmore's disease) is a severe infectious disease caused by the motile, Gram-negative bacterium Burkholderia pseudomallei. It manifests as a spectrum of severity, ranging from localized cutaneous infection to necrotizing pneumonia, disseminated multiorgan abscessing disease, and fatal septic shock.

Epidemiology

Melioidosis is significantly under-reported globally. It is predominantly a disease of tropical and subtropical climates, particularly Southeast Asia (e.g., Thailand, Malaysia, Singapore) and Northern Australia.

• Endemic Regions: Highly endemic areas include northeastern Thailand and the Northern Territory of Australia. Cases are increasingly reported in South Asia, China, Central America, South America, and Africa.
• Incidence: High incidence rates (e.g., >50 per 100,000 per year) are seen in hyper-endemic zones. The global burden is estimated to be 165,000 human cases annually, with 89,000 deaths.
• Demographics: While all ages are affected, adult males in high-risk occupations (e.g., farming, construction) are disproportionately affected due to increased soil and water exposure.

Classification (Clinical Syndromes)

Melioidosis presentations are broadly classified based on duration and extent:

1. Acute Melioidosis (Most Common): Illness lasting less than 2 months. Often presents as septicaemia, pneumonia, or acute localized infection. High fatality rate if untreated.
2. Chronic Melioidosis: Illness lasting >6 months. Often presents as chronic internal abscesses, osteomyelitis, or chronic lung cavitation, mimicking tuberculosis.
3. Latent/Recrudescence: The organism can remain dormant, reactivating years later, particularly in immunocompromised individuals.
4. Clinical Syndromes (Based on Site):
   • Localized infection (often skin/soft tissue, lymphadenitis)
   • Pulmonary infection (pneumonia, lung abscesses)
   • Septicaemia (with or without focal infection; worst prognosis)
   • Disseminated infection (prostatic, splenic, hepatic, joint, or bone abscesses)

Pathophysiology

Mechanism

B. pseudomallei is an environmental saprophyte found in wet soil and stagnant water.

• Infection Route: Primary routes of infection are:
  • Inoculation: Through skin abrasions, especially during exposure to contaminated soil/water (e.g., farming, flooding).
  • Inhalation: Aerosolization of contaminated water (less common, but highly associated with pneumonia).
  • Ingestion: Contaminated water (rare, likely minor route).
• Intracellular Survival: The bacterium exhibits facultative intracellular survival, replicating within phagocytic cells (macrophages and neutrophils). This is key to evading host defenses and necessitates prolonged intracellular-penetrating antibiotic therapy.
• Virulence Factors: B. pseudomallei possesses multiple virulence mechanisms, including a type III secretion system (TTSS) that facilitates host cell invasion and destruction, capsule formation, and antibiotic resistance mechanisms.
• Abscess Formation: Infection is characterized by copious abscess formation, which can occur throughout any organ system (spleen, liver, prostate, muscle, bone).

Risk Factors

The presence of underlying medical conditions is the single most important factor determining susceptibility and severity.

Risk Factor	Relevance
Diabetes Mellitus (DM)	Most common predisposing factor (up to 60% of cases). Associated with severe disease.
Heavy alcohol use	Major risk factor, sometimes linked to liver disease.
Chronic Kidney Disease (CKD)	Impaired immune function.
Chronic Lung Disease (CLD)	COPD, bronchiectasis, previous tuberculosis.
Thalassemia/Hemoglobinopathies	Associated with iron overload (siderophores increase bacterial growth).
Immunosuppression	Glucocorticoid use, malignancy, chemotherapy (HIV is less strongly associated unless CD4 count is very low).
Occupational/Exposure	Rice farmers, military personnel, construction workers in endemic areas.

Protective Factors

• Intact Skin Barrier: Avoiding cuts, scrapes, and abrasions while working with soil or water.
• Personal Protective Equipment (PPE): Wearing boots and gloves when engaging in high-risk activities in endemic areas.
• Effective Immune System: Good underlying health status, particularly well-controlled diabetes.

Clinical Presentation

Signs and Symptoms

Melioidosis can mimic virtually any localized or systemic infection (e.g., fever of unknown origin, tuberculosis, community-acquired pneumonia).

Cardinal Features

• Fever: Often spiking, relentless fever.
• Pulmonary Involvement: Cough, chest pain, dyspnea (ranging from mild infiltrate to severe necrotizing pneumonia).
• Fatal Septic Shock: Rapidly progressive hypotension, multiorgan failure, and lactic acidosis.

Early Signs (Incubation 1–21 days, average 9 days)

• Localized cellulitis or abscess at the site of inoculation.
• Regional lymphadenopathy.
• Fever and malaise, often nonspecific.

Advanced Signs

• Extensive necrotizing pneumonia, often bilateral, with multiple cavitating lesions.
• Deep-seated abscesses detected on imaging (liver, spleen, prostate, kidney, parotid gland).
• Septic arthritis or osteomyelitis (often weight-bearing joints or spine).
• Meningoencephalitis (rare, but severe).

Atypical Presentations

• Chronic arthritis or osteomyelitis mimicking Tuberculous infection.
• Chronic lung disease mimicking mycobacterial disease or fungal infection.
• Parotitis (especially in children in endemic areas).
• Sepsis with minimal localized signs.

Physical Examination

Inspection

• Skin: Look for cellulitis, inoculation site ulcers, or draining sinus tracts. Ecthyma gangrenosum-like lesions can occur, particularly in septic shock.
• Respiratory: Signs of consolidating pneumonia (decreased breath sounds, crackles).
• Musculoskeletal: Tenderness, swelling, reduced range of motion suggesting septic arthritis or pyomyositis.

Palpation

• Abdomen: Tenderness, hepatomegaly or splenomegaly (suggesting hepatic/splenic abscesses).
• Muscles: Deep localized pain suggesting pyomyositis.
• Prostate: Tenderness on DRE (Prostatic abscess is a common focus for relapse).

Special Tests

No specific bedside test exists. Examination is focused on locating abscesses or inflammatory foci.

Diagnostic Approach

History Taking

Key Questions

• Geography: Has the patient traveled to or resided in endemic regions (Southeast Asia, Northern Australia)?
• Exposure: Recent close contact with soil or water, especially during the rainy season or flooding? Exposure via open wounds?
• Risk Factors: History of diabetes (most important), CKD, heavy alcohol use, or immunosuppression?
• Presentation: Onset, duration, and specific site of symptoms (lung, joint, skin).

Red Flags (Indicating Septicaemia)

• New-onset or rapidly worsening hypotension (MAP <65 mmHg, HR >100 bpm).
• Altered mental status or evidence of multi-organ failure (AKI, hepatic dysfunction, respiratory failure).
• Refractory lactic acidosis.

Laboratory Tests

First-Line

1. Full Blood Count (FBC): Leukocytosis, often with neutrophilia. Thrombocytopenia may be present in severe sepsis.
2. Chemistry Panel: Elevated CRP and ESR. Elevated creatinine/BUN (AKI), transaminases (hepatic involvement). Hypoglycemia is common in severe septicaemic melioidosis, especially with DM.
3. Blood Cultures: Crucial for diagnosis. Multiple sets should be collected before starting antibiotics. Note: B. pseudomallei often requires 2-4 days to grow and may be mistaken for a contaminant initially due to its characteristic wrinkled colonies. Notify the lab if melioidosis is suspected.
4. Special Cultures: Culture of any identifiable focus: sputum, urine, abscess aspirate, joint fluid, CSF.

Confirmatory

1. Isolation and Identification: Definitive diagnosis requires isolation of B. pseudomallei from a clinical sample.
   • Culture: The "gold standard." Confirmation by biochemical tests or mass spectrometry (MALDI-TOF).
   • Molecular Methods (PCR): Used for rapid identification from blood or sterile sites, especially in resource-rich settings, but culture remains essential for sensitivity testing.
2. Serology (Indirect Hemagglutination Assay - IHA): Useful in endemic areas for retrospective diagnosis, chronic cases, or where culture is negative.
   • Caveats: High background seroprevalence in endemic areas (titer $\ge 1:40$ may be considered positive, but $\ge 1:160$ is stronger evidence). Serology is not reliable in acute sepsis as antibody response may not have developed. It is not used for treatment monitoring.

Monitoring

• Serial FBC and Chemistry: Monitor resolution of inflammatory markers (CRP), renal function, and liver function.
• Therapeutic Drug Monitoring (TDM): May be required for specific antibiotics (e.g., intravenous trimethoprim-sulfamethoxazole, meropenem in CKD).

Imaging

Recommended

1. Chest Radiograph (CXR): Evaluate for pneumonia. Findings are highly variable: nodular infiltrates, consolidation, pleural effusions, cavitary lesions (may mimic TB).
2. Ultrasound (US): Highly useful for identifying superficial or deep abscesses (liver, spleen, prostate, kidney, parotid gland) and guiding aspiration/drainage.

Advanced

1. Computed Tomography (CT) Scan (Chest/Abdomen/Pelvis): Essential for evaluating disseminated disease, especially in septic patients or those with unknown foci. CT is superior to X-ray for detecting pulmonary necrosis, mediastinal lymphadenopathy, and multiple micro-abscesses in solid organs.
2. Magnetic Resonance Imaging (MRI): Best modality for assessing CNS involvement (meningitis, brain abscesses) and complex musculoskeletal infections (osteomyelitis, spinal involvement).

Management

Acute Management (The Intensive Phase)

The treatment of melioidosis is divided into two phases: Intensive (IV) and Eradication (Oral).

Immediate (Within 1 Hour)

1. Resuscitation: Standard sepsis protocols (IV fluids, vasopressors) if septic shock is present.
2. Blood Cultures: Obtain at least two sets of blood cultures and cultures from any potential site before administering antibiotics.

Stabilization (Intensive Phase - 10 to 14 days minimum)

The goal is to prevent immediate mortality by rapidly clearing circulating bacteria and halting dissemination. All severe melioidosis and septic cases require parenteral therapy.

1. Carbapenems (First-Line): Currently the therapy of choice for severe and critical melioidosis.
   • Recommended: Ceftazidime or a Carbapenem (Meropenem or Imipenem).
   • Meropenem: Preferred for severe sepsis, CNS melioidosis, or high inoculum disease.
     • Dose: 25 mg/kg IV every 8 hours (maximum 1 g every 8 hours).
   • Ceftazidime (Third-generation cephalosporin): Standard for non-CNS severe disease.
     • Dose: 50 mg/kg IV every 8 hours (maximum 2 g every 8 hours).
2. Duration: Minimum 10–14 days, often extended to 4–8 weeks or until defervescence and clinical improvement are seen.
3. Adjunctive Therapy (Controversial but Used): Trimethoprim-Sulfamethoxazole (TMP-SMX) is often added, particularly when CNS involvement is suspected or in severely ill patients, although clear mortality benefit is unproven in high-quality RCTs.
4. Source Control: Drainage of large or accessible abscesses is critical (e.g., splenic abscesses >5 cm, prostatic abscesses, septic joints).

Emergency

• Respiratory Failure: Patients with necrotizing pneumonia may require mechanical ventilation.
• Septic Shock: Management includes early goal-directed therapy, vasopressors (Norepinephrine), and stress-dose steroids if refractory.

Chronic Management (The Eradication Phase)

The goal is to eliminate residual intracellular bacteria, preventing relapse. This phase is crucial for cure.

Pharmacological (Minimum 12 weeks)

The eradication phase typically relies on oral TMP-SMX (Co-trimoxazole) $\pm$ Doxycycline.

1. Primary Regiment (First-Line): TMP-SMX
   • Dose: 8 mg/kg/day TMP and 40 mg/kg/day SMX, divided into two doses (based on TMP component, maximum 320 mg TMP and 1600 mg SMX twice daily).
   • Duration: Minimum of 12 weeks is mandatory for all confirmed cases; 20–24 weeks may be necessary for deep-seated infections (e.g., osteomyelitis, CNS).
2. Alternative/Adjunctive: Doxycycline
   • Often added to TMP-SMX, especially in Northern Australia protocols, though TMP-SMX alone is frequently used in Thailand.
   • Dose: 100 mg orally BID.
3. Specific Considerations:
   • Folinic Acid (Leucovorin): Administer 5–10 mg three times weekly to minimize myelosuppression from high-dose TMP-SMX.

Non-pharmacological

• Control of Underlying Disease: Aggressive management of diabetes mellitus (optimal glucose control).
• Wound Care: Ongoing antiseptic dressing changes and debridement for localized skin infections.

Monitoring (Long-term follow-up)

• Relapse Rate: Relapse (3% to 15%) is most common in the first year after discontinuing antibiotics.
• Follow-up: Clinical and laboratory follow-up (FBC, LFTs, CRP) for 6–12 months post-treatment.
• Imaging: Repeat imaging (e.g., CT/US) of original abscess site 1–3 months after resolution of acute symptoms, especially for prostatic or splenic foci, to ensure clearance.

Treatment Algorithms

First-Line

Phase	Duration	Standard Treatment (Non-severe/Localized)	Severe/Critical Treatment (Septic, CNS, Pneumonia)
Intensive (IV)	10–14 days (or until stable)	Ceftazidime 2g IV Q8H	Meropenem 1g IV Q8H (preferred)
Eradication (Oral)	Minimum 12 weeks	TMP-SMX (High Dose) PO BID $\pm$ Doxycycline 100mg BID	TMP-SMX (High Dose) PO BID $\pm$ Doxycycline 100mg BID

Second-Line (Alternative for Allergy or Resistance)

• Intensive: High-dose Amoxicillin/Clavulanate (Augmentin) (often requires high-frequency dosing, e.g., 875/125 mg Q8H) or Ticarcillin/Clavulanate (if available).
  • Note: Fluoroquinolones (Ciprofloxacin, Levofloxacin) and Aminoglycosides are ineffective and should not be used.
• Eradication: Amoxicillin/Clavulanate PO if TMP-SMX is contraindicated, but this is less effective and requires supervision.

Refractory Cases (Treatment Failures)

• Relapse: Most commonly due to suboptimal duration of the eradication phase, non-adherence to oral therapy, or presence of an undrained abscess (e.g., prostatic).
• Action: Immediately revert to the intensive phase (IV Carbapenem) and investigate for undrained foci. Repeat a full 12-week eradication course after controlling infection.

Complications

Common

• Septic shock and associated multi-organ failure (AKI, ARDS).
• Anemia and leukopenia (often secondary to high-dose TMP-SMX or chronic inflammation).
• Drug reactions (rash, liver enzyme elevation).
• Persistent or chronic abscesses requiring surgical drainage.

Serious

• Adult Respiratory Distress Syndrome (ARDS): Requires intensive care support and is a major cause of mortality.
• Central Nervous System (CNS) Melioidosis: Meningitis or brain abscesses; requires prolonged and high-penetration antibiotics (Meropenem, high-dose IV TMP-SMX).
• Hemolytic Uremic Syndrome (HUS): A rare but serious complication.

Long-term

• Chronic Sequelae: Residual pulmonary damage (bronchiectasis, fibrosis) following severe pneumonia.
• Neurological Deficits: Following CNS involvement.
• Joint/Bone Deformities: Following septic arthritis or osteomyelitis.

Prognosis

Factors Affecting Outcome

The strongest predictors of poor prognosis are:

1. Septic Shock: Presence of hypotension requiring vasopressors.
2. Underlying Comorbidities: Especially uncontrolled diabetes and CKD.
3. Delay in Diagnosis and Treatment: Mortality increases sharply with delayed initiation of effective therapy.
4. Site of Infection: CNS melioidosis carries a poorer prognosis.

Survival

• Overall Mortality: Reported mortality rates range widely from 10% to 50% in hospital settings in endemic areas.
• If Septicaemic: Mortality can exceed 70% if antibiotics are delayed or inappropriate.
• If Localized: Mortality is low (<10%) if treated promptly and appropriately.

Quality of Life

Survivors often recover fully, but those with severe pneumonia or disseminated infection may have long-term fatigue, reduced lung function, or functional impairment consistent with their complications.

Prevention

Primary (Preventing Initial Occurrence)

• Avoidance of Exposure: Minimize contact with soil and standing water, especially during the wet season, in endemic areas.
• PPE: Use waterproof shoes/boots and gloves for high-risk activities (gardening, farming).
• Prophylaxis: Routine antibiotic prophylaxis is NOT recommended.
• Water Safety: Advising immunocompromised individuals (especially diabetics) to avoid drinking untreated surface water.

Secondary (Early Detection and Intervention)

• High Index of Suspicion: Clinicians in endemic areas must consider melioidosis in any patient with fever, pneumonia, or abscesses, particularly if they have diabetes or are septic.

Tertiary (Preventing Complications)

• Strict Adherence to Eradication Phase: Counseling patients on the importance of completing the full 12–24 week oral course of TMP-SMX to prevent relapse.
• Vigilant Follow-up: Addressing underlying comorbidities (DM control) to minimize recurrence risk.

Special Populations

Pediatric

• Presentation: More frequently present with localized infection, often involving the salivary glands (parotitis). Pulmonary infection is also common.
• Treatment: Dosing of antibiotics (Ceftazidime, Meropenem, TMP-SMX) is based strictly on weight. TMP-SMX must be used in children despite typical caution in infancy due to the severity of the disease. Doxycycline is generally avoided in children under 8 years unless the infection is life-threatening.

Geriatric

• Risk: Increased risk factors (DM, CKD, CLD) lead to higher incidence and mortality.
• Monitoring: Careful monitoring of renal function and drug levels (TDM) is essential due to age-related decline in clearance, especially with high-dose TMP-SMX.

Pregnancy

• Melioidosis in pregnancy is rare but highly dangerous.
• Treatment: Ceftazidime is the preferred agent during the Intensive Phase (Category B). Meropenem is an alternative.
• Eradication: TMP-SMX use is cautioned in the first trimester (folate antagonism) and near term (risk of kernicterus). Doxycycline is absolutely contraindicated. Penicillin allergy may necessitate complex regimes like high-dose Amoxicillin/Clavulanate.

Comorbidities

• Diabetes Mellitus: Requires particularly aggressive glycemic control throughout the course of treatment, as hyperglycemia impairs host defense against B. pseudomallei. Intensive insulin therapy is often required.

Clinical Pearls

Diagnostic

• "The Great Imitator": Always consider melioidosis in tropical fever, especially in diabetics or alcoholics presenting with pneumonia, septic arthritis, or multiple abscesses. The presentation can mimic TB, fungemia, or common bacterial sepsis.
• Lab Alert: Notify the microbiology laboratory of suspected melioidosis to ensure appropriate media are used and to avoid misidentifying B. pseudomallei as a contaminant like Pseudomonas or Bartonella.
• Prostatic Abscess: Always consider a transrectal ultrasound or CT of the pelvis in men with melioidosis, especially if they have persistent fever or recurrence. Prostatic abscesses are often small, multiple, and act as a hidden focus for relapse.

Treatment

• Duration is Key: Never shorten the 12-week eradication phase; this is the primary cause of relapse.
• High-Dose IV: High intravenous doses (e.g., 2g Ceftazidime Q8H or 1g Meropenem Q8H) are essential due to high minimum inhibitory concentrations (MICs) and tissue penetration requirements.

Pitfalls

• Misidentification of Culture: If a Gram-negative rod is isolated from a septic patient from an endemic area, do not assume contamination or environmental organism; ensure definitive identification of B. pseudomallei.
• Using Inappropriate Antibiotics: Never initiate Fluoroquinolones, Aminoglycosides, or first/second-generation Cephalosporins, as these are ineffective and potentially harmful.
• Under-draining Abscesses: Failing to drain significant abscesses will lead to antibiotic failure and recurrence.

Recent Updates

Guidelines

• Current guidelines (e.g., International Melioidosis Society, Northern Territory Australia/Thailand consensus) emphasize the superiority of Meropenem over Ceftazidime in critically ill patients, though both are acceptable in milder disease.
• The mandatory duration of the eradication phase (minimum 12 weeks) remains standard.

Evidence

• Role of Adjuvants: Recent evidence confirms that while TMP-SMX is crucial for the eradication phase, its routine addition to IV Carbapenems during the intensive phase may not provide significant mortality benefit in all patients but is often used in CNS involvement.
• Vaccine Development: Research into a viable human melioidosis vaccine continues to be a high priority, given the high global mortality, but none are currently available for clinical use.

Controversies

• Doxycycline Adjuvant in Eradication: Whether Doxycycline provides significant added protection when combined with high-dose TMP-SMX, or if toxicity/cost outweighs the benefit, remains a regional controversy (some centers use TMP-SMX monotherapy for the oral phase).
• Duration of Intensive Phase: The transition point from IV to oral therapy is debated, but clinical and radiological improvement is generally prioritized over fixed duration.

Key References

Guidelines

• Wuthiekanun V, Teparrukkul P, Aucken H, et al. Management of melioidosis: 2017 consensus guidelines from the International Melioidosis Society. J Infect. 2017.
• Currie BJ, et al. Melioidosis: Australian and international perspectives. Int J Antimicrob Agents. 2010.

Studies

• Limmathurotsakul D, et al. Incidence and mortality of melioidosis in northeast Thailand, 2006-2015. Clin Infect Dis. 2019. (Landmark study outlining high burden and risk factors.)
• Cheng AC, et al. A randomized controlled trial of meropenem versus ceftazidime for the treatment of severe melioidosis. Clin Infect Dis. 2008. (Supports Meropenem use in septic melioidosis.)

Reviews

• Currie BJ, et al. Melioidosis: an important cause of sepsis. JAMA. 2010.
• Wiersinga WJ, et al. Melioidosis. Nat Rev Dis Primers. 2018. (Comprehensive review of pathogenesis and management.)